Research Paper Volume 12, Issue 14 pp 14406—14417

Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway

Figure 4. Osthole partially reversed the cisplatin resistance of CD133+ HCC cells through the PTEN pathway. (A) QRT-PCR analysis was used to test the effect of osthole (10 μmol/L) on changing the expression of PTEN at the mRNA level. #P<0.05 vs. control group, &P<0.05 vs. cisplatin group. (B) Western blot analysis was used to evaluate the effect of osthole (10 μmol/L) and PTEN siRNA on affecting the expression of PTEN at the protein level. (C) Transfection with PTEN siRNA increased the cell viability of CD133+ Huh7 and HepG2 cells which were co-treated with osthole (10 μmol/L) and cisplatin (5 μmol/L). #P<0.05 vs. cisplatin+control siRNA group, &P<0.05 vs. cisplatin+osthole+control siRNA group. (D) Transfection with PTEN siRNA decreased the apoptotic rate of CD133+ Huh7 and HepG2 cells which were co-treated with osthole (10 μmol/L) and cisplatin (5 μmol/L). #P<0.05 vs. cisplatin+control siRNA group, &P<0.05 vs. cisplatin+osthole+control siRNA group.